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Aging is accompanied by changes in neurotransmission. To advance our understanding of how aging modifies
specific neural circuitries, we examined serotonergic and cholinergic stimulation with resting state functional
magnetic resonance imaging (RS-fMRI) in young and older adults. The instant response to the selective serotonin
reuptake inhibitor citalopram (30mg) and the acetylcholinesterase inhibitor galantamine (8mg) was measured in
12 young and 17 older volunteers during a randomized, double blind, placebo-controlled, crossover study. A
powerful dataset consisting of 522 RS-fMRI scans was obtained by acquiring multiple scans per subject before and
after drug administration. Group treatment interaction effects on voxelwise connectivity with ten functional
networks were investigated (p< .05, FWE-corrected) using a non-parametric multivariate analysis technique with
cerebrospinal fluid, white matter, heart rate and baseline measurements as covariates. Both groups showed a
decrease in sensorimotor network connectivity after citalopram administration. The comparable findings after
citalopram intake are possibly due to relatively similar serotonergic systems in the young and older subjects.
Galantamine altered connectivity between the occipital visual network and regions that are implicated in learning
and memory in the young subjects. The lack of a cholinergic response in the elderly might relate to the well-
known association between cognitive and cholinergic deterioration at older age.Introduction
During the process of aging, there is a decline in brain function (Li and
Lindenberger, 2002). Reduced synaptic plasticity, transmitter release and
receptor availability in the central nervous system (CNS) might affect
cognitive and behavioral performance (Li et al., 2001; Mahncke et al.,
2006). Impaired cholinergic transmission has been associated with
age-related disruptions in attention and memory storage and retrieval,
(Decker, 1987; Dumas and Newhouse, 2011; Gallagher and Colombo,
1995; Hasselmo, 1999), whereas serotonin (5- hydroxytryptamine; 5-HT)
dysregulation may contribute to the increased prevalence of depressive
symptoms in the elderly (Daubert and Condron, 2010; Gareri et al., 2002;
Meltzer et al., 1998).
Magnetic resonance imaging (MRI) of resting state functional con-
nectivity cannot be used to measure neurotransmission directly, but is
commonly applied to improve insight into neurotransmitter function byPsychology, Unit Methodology and S
c. This is an open access article undestudying brain networks after a pharmacological intervention (Borsook
et al., 2006; Honey et al., 2003; Khalili-Mahani et al., 2015; Klumpers
et al., 2012; Lu and Stein, 2014; Niesters et al., 2014). With regard to
aging, the effects of serotonergic and cholinergic challenges on brain
connectivity are especially relevant as compounds acting on these sys-
tems are used to treat depression and dementia (Carr and Lucki, 2011;
Soreq and Seidman, 2001).
Acute or short-term dosing of drugs that prevent the presynaptic re-
uptake of serotonin seems to counteract the observed increased con-
nectivity patterns in depression (Sundermann et al., 2014), showing
reduced connectivity with several cortical and subcortical areas in
healthy and depressed young subjects (Klaassens et al., 2015, 2017a; Li
et al., 2013; McCabe and Mishor, 2011; McCabe et al., 2011; Schaefer
et al., 2014; Van de Ven et al., 2013; Van Wingen et al., 2014). Cholin-
esterase inhibitors (AChEIs) cause connectivity enhancement of regions
that are important for learning, memory and executive control aftertatistics, Leiden, The Netherlands.























Fig. 1. Schematic overview of the study design. Each subject received citalopram, galantamine and placebo on three different study days. On each study day there were three moments
of administration. The second administration only took place when subjects tolerated the first dose well (did not vomit or feel too nauseous). At baseline, two RS-fMRI scans were acquired,
followed by the NeuroCart® test battery. On all study days, subjects received 2mg of granisetron 30min before drug administration, to prevent for possible side effects of citalopram and/or
galantamine. After drug administration, four RS-fMRI scans were acquired at time points T¼ 2.5, 3.5, 4.5 and 6 h post dosing, each time followed by the NeuroCart® test battery. During the
day, nine blood samples were taken to measure the concentrations of citalopram, desmethylcitalopram, galantamine, cortisol and prolactin.
B.L. Klaassens et al. NeuroImage 169 (2018) 312–322long-term treatment in patients with Alzheimer's disease (Blautzik et al.,
2016; Goveas et al., 2011; Griffanti et al., 2016; Li et al., 2012; Sol-
e-Padulles et al., 2013) and immediately after administration in young
subjects (Klaassens et al., 2017a).
Despite evidence of cholinergic and serotonergic alterations with
aging, it is unknown how the corresponding connectivity pathways are
altered at older age. There is little proof of differentiated effects of se-
lective serotonin reuptake inhibitors (SSRIs) and AChEIs on subjective
and cognitive measures between healthy young and older subjects
(Dumont et al., 2005; Repantis et al., 2010; Vanlaar et al., 1995). How-
ever, during senescence 5-HT receptor density declines (Arranz et al.,
1993) and the cholinergic system has been suggested to have diminished
and more variable responsiveness (Bartus, 1979; Decker, 1987). Given a
negative association of aging with neuromodulation and brain function,
we anticipate that effects of the SSRI citalopram and the AChEI galant-
amine on resting state connectivity are more constrained in older
compared to young subjects.
Material and methods
Subjects
Twelve healthy young volunteers (mean age 22.1 2.7; age range
18–27; 6 female/6 male; body mass index range 21–28 kg/m2) and 17
healthy older adults (mean age 71.2 6.1; age range 61–79; 9 female/8
male; body mass index range 22–31 kg/m2) were included in the study.
All subjects underwent a thorough medical screening at the Centre for
Human Drug Research (CHDR) to investigate whether they met the
inclusion and exclusion criteria. They had a normal history of physical
and mental health and were able to refrain from using nicotine and
caffeine during study days. Exclusion criteria included a positive drug
or alcohol test on study days, regular excessive consumption of alcohol
(>4 units/day), caffeine (>6 units/day) or cigarettes (>5 cigarettes/
day), use of concomitant medication 2 weeks prior to study participa-
tion and involvement in an investigational drug trial 3 months prior to
administration. The study was approved by the medical ethics com-
mittee of the Leiden University Medical Center (LUMC). Written
informed consent was obtained from each subject prior to study
participation.313Study design
Part of the data, showing drug effects in young adults, have been
described previously (Klaassens et al., 2017a). This was a single center,
double blind, placebo-controlled, crossover study with citalopram 30mg
and galantamine 8mg. Citalopram has an average time point of
maximum concentration (Tmax) of 2–4 h, with a half-life (T½) of 36 h. For
galantamine, Tmax¼ 1–2 h and T½¼ 7–8 h. To correct for the different
pharmacokinetic (PK) profiles and obtain all pharmacodynamic mea-
sures within an equal time frame at around the Tmax of both compounds,
citalopram was administered earlier than galantamine. In addition, since
a lower dose of SSRIs is recommended in elderly compared to young
subjects (Lotrich and Pollock, 2005), it was decided to retain the op-
portunity of administering a lower dose of citalopram in elderly than in
young subjects. Therefore, citalopram 20mg was administered at
T¼ 0 h, followed by a second dose of 10mg at T¼ 1 h (only if the first
dose was tolerated). Galantamine was given as a single 8mg dose at
T¼ 2 h. Blinding was maintained by concomitant administration of
double-dummy placebo's at all three time points. All subjects also
received an unblinded dose of granisetron 2mg at T¼0.5 h, to prevent
the most common drug-induced adverse effects of nausea and vomiting.
Several outcome measures were included in this study that were each
separately analyzed as described in the next sections. Six resting state
fMRI (RS-fMRI) scans were acquired during study days, two at baseline
and four after administering citalopram, galantamine or placebo (at
T¼ 2.5, 3.5, 4.5 and 6 h). Each scan was followed by performance of
computerized cognitive tasks (taken twice at baseline) on the NeuroCart®
test battery, developed by the CHDR for quantifying pharmacological
effects on the CNS (Dumont et al., 2005; Gijsman et al., 2002; Liem-
Moolenaar et al., 2011). By including multiple measurements during
the Tmax interval, this repeated measures profile increases the statistical
power of the analysis and allows for identification of time related effects,
associated with changing drug concentrations related to absorption,
distribution, metabolism and excretion. Nine blood samples were taken
during the course of the day to define the PK profile of citalopram, cit-
alopram's active metabolite desmethylcitalopram, galantamine and
concentrations of cortisol and prolactin (Jacobs et al., 2010; Umegaki
et al., 2009). Washout period between study days was at least 7 days. An
overview of the study design is provided in Fig. 1.
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Pharmacokinetics
Pharmacokinetic parameters for citalopram, galantamine and cit-
alopram's active metabolite desmethylcitalopramwere calculated using a
non-compartmental analysis to validate the choice of time points of
pharmacodynamic endpoints and, in case of equal absorption rates, in-
crease confidence in pharmacodynamic outcomes (RS-fMRI, NeuroCart®,
neuroendocrine measures). Blood samples were collected in 4mL EDTA
plasma tubes at baseline and 1, 2, 2.5, 3, 3.5, 4.5 and 6 h post dosing,
centrifuged (2000g for 10min) and stored at 40 C until analysis with
liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Neuroendocrine variables
Blood samples were also obtained to determine cortisol and prolactin
concentrations. Serum samples were taken in a 3.5mL gel tube at baseline
(twice) and 1, 2, 2.5, 3.5, 4.5 and 6 h post dosing, centrifuged (2000g for
10min) and stored at 40 C until analysis. Serum concentrations were
quantitatively determinedwith electrochemiluminescence immunoassay.
NeuroCart® test battery
Each RS-fMRI scan was followed by functional CNS measures outside
the scanner using the computerized NeuroCart® test battery measuring
alertness, mood and calmness (Visual Analogue Scales (VAS) Bond &
Lader), nausea (VAS Nausea), vigilance and visual motor performance
(Adaptive Tracking task), reaction time (Simple Reaction Time task),
attention, short-term memory, psychomotor speed, task switching and
inhibition (Symbol Digit Substitution Test and Stroop task), working
memory (N-back task) and memory imprinting and retrieval (Visual
Verbal Learning Test) (Bond and Lader, 1974; Borland and Nicholson,
1984; Laeng et al., 2005; Lezak, 2004; Lim et al., 2008; Norris, 1971;
Rogers et al., 2004; Stroop, 1935; Wechsler, 1981). The Visual Verbal
Learning Test was only performed once during each day (at 3 and 4 h post
dosing) as the test itself consists of different trials (imprinting and
retrieval). Duration of each series of NeuroCart® brain function tests was
approximately 20min. To minimize learning effects, training for the
NeuroCart® tasks occurred during the screening visit within 3 weeks
prior to the first study day.
MR imaging
Scanning was performed at the LUMC on a Philips 3.0 T Achieva MRI
scanner (Philips Medical System, Best, The Netherlands) using a 32-
channel head coil. During the RS-fMRI scans, all subjects were asked to
close their eyes while staying awake. Instructions were given prior to
each scan on all study days. T1-weighted anatomical images were ac-
quired once per visit. To facilitate registration to the anatomical image,
each RS-fMRI scan was followed by a high-resolution T2*-weighted echo-
planar scan.
RS-fMRI data were obtained with T2*-weighted echo-planar imaging
(EPI) with the following scan parameters: 220 whole brain volumes,
repetition time (TR)¼ 2180ms; echo time (TE)¼ 30ms; flip angle¼ 85;
field-of-view (FOV) ¼ 220  220  130 mm; in-plane voxel
resolution ¼ 3.44  3.44 mm, slice thickness ¼ 3.44 mm, including 10%
interslice gap; acquisition time 8 min. For 3D T1-weighted MRI the
following parameters were used: TR ¼ 9.7 ms; TE ¼ 4.6 ms; flip
angle ¼ 8; FOV ¼ 224  177  168 mm; in-plane voxel
resolution ¼ 1.17  1.17 mm; slice thickness ¼ 1.2 mm; acquisition time
5 min. Parameters of high-resolution T2*-weighted EPI scans were set to:
TR¼ 2200ms; TE¼ 30ms; flip angle¼ 80; FOV¼ 220 220 168mm;
in-plane voxel resolution ¼ 1.96  1.96 mm; slice thickness ¼ 2.0 mm;
acquisition time 30 s.
Statistical analysis
Pharmacokinetics
Maximum plasma concentrations (Cmax) and time of Cmax (Tmax) were314obtained directly from the plasma concentration data. The area under the
plasma concentration versus time curve was calculated from time zero to
the time of the last quantifiable measured plasma concentration (AUC0-
last). To investigate differences between groups, PK parameters were
analyzed using a mixed effects model with group as fixed effect (SAS for
Windows V9.4; SAS Institute, Inc., Cary, NC, USA).
Neuroendocrine variables
Treatment (drug versus placebo) x group (young versus older sub-
jects) interaction effects on cortisol and prolactin concentrations were
investigated using a mixed effects model with treatment, time, group,
visit, treatment by time, treatment by group and treatment by group by
time as fixed effects, subject, subject by treatment and subject by time as
random effects and the average of the period baseline (pre-dose) values
as covariate (SAS for Windows V9.4; SAS Institute, Inc., Cary, NC, USA).
The data were not normally distributed and therefore log-transformed
before analysis and back transformed after analysis.
NeuroCart® test battery
All post-dose repeatedly measured NeuroCart® measures were
analyzed using the same mixed effects model as for neuroendocrine
variables. As data of the Simple Reaction Time task were not normally
distributed, these data were log-transformed before analysis and back
transformed after analysis. The data of the Visual Verbal Learning Test
were analyzed using a mixed effects model with treatment, group, visit
and treatment by group as fixed effects and subject as random effect.
MR imaging
All analyses were performed using the Functional Magnetic Reso-
nance Imaging of the Brain (FMRIB) Software Library (FSL, Oxford,
United Kingdom) version 5.0.7 (Jenkinson et al., 2012; Smith et al.,
2004; Woolrich et al., 2009).
Data preprocessing. Each individual functional EPI image was inspected,
brain-extracted and corrected for geometrical displacements due to head
movement with linear (affine) image registration (Jenkinson et al., 2002;
Smith, 2002). Images were spatially smoothed with a 6 mm full-width
half-maximum Gaussian kernel. Registration parameters for non-
smoothed data were estimated to transform fMRI scans into standard
space and co-registered with the brain extracted high resolution T2*-
weighted EPI scans (with 6 degrees of freedom) and T1 weighted im-
ages (using the Boundary-Based-Registration method) (Greve and Fischl,
2009). The T1-weighted scans were non-linearly registered to the MNI
152 standard space (the Montreal Neurological Institute, Montreal, QC,
Canada) using FMRIB's Nonlinear Image Registration Tool. Registration
parameters were estimated on non-smoothed data to transform fMRI
scans into standard space after Automatic Removal Of Motion Artifacts
based on Independent Component Analysis (ICA-AROMA vs0.3-beta).
ICA-AROMA attempts to identify and remove motion related noise
components by investigating its temporal and spatial properties. As rec-
ommended, high pass temporal filtering (with a high pass filter of 150 s)
was applied after denoising the fMRI data with ICA-AROMA (Pruim et al.,
2015a, 2015b).
Estimation of network connectivity. RS-fMRI networks were extracted from
each individual denoised RS-fMRI dataset (29 subjects x 3 days  6
scans¼ 522 datasets) with a dual regression analysis (Beckmann et al.,
2009; Filippini et al., 2009) based on 10 predefined standard network
templates as used in our previous research (Klaassens et al., 2015,
2017a). These standard templates have been identified using a data-
driven approach (Smith et al., 2009) and comprise the following net-
works: three visual networks (consisting of medial, occipital pole, and
lateral visual areas), default mode network, cerebellar network, senso-
rimotor network, auditory network, executive control network and two
frontoparietal networks (left and right). Time series of white matter
Table 1
Pharmacokinetics of citalopram, desmethylcitalopram and galantamine in young and older adults.







Young adults Older adults Young adults Older adults Young adults Older adults
Tmax 3.0 1.2 3.4 1.1 0.319 4.9 1.3 4.0 1.3 0.068 2.7 1.1 4.5 1.1 <0.001
Cmax 35.8 6.3 41.8 11.7 0.165 3.0 1.1 3.5 1.8 0.332 40.7 10.4 41.8 12.2 0.811
AUC0-last 146.0 25.2 165.0 43.6 0.259 11.7 4.8 13.3 7.1 0.500 95.1 27.7 104 40.2 0.494
Abbreviations: PK¼ pharmacokinetic; Tmax¼ time point (h) of maximum concentration; Cmax¼maximum concentration (ng/mL); AUC0-last ¼ area under the plasma concentration versus
time curve (ng*h/mL).
B.L. Klaassens et al. NeuroImage 169 (2018) 312–322(measured from the center of the corpus callosum) and cerebrospinal
fluid (measured from the center of lateral ventricles) were added as
confound regressors in this analysis to account for non-neuronal signal
fluctuations (Birn, 2012). With the dual regression method, spatial maps
representing voxel-to-network connectivity were estimated for each
dataset and network separately in two stages. First, the weighted network
maps were used in a spatial regression into each dataset. This stage
generated 12 time series per dataset that describe the average temporal
course of signal fluctuations of the 10 networks plus 2 confound re-
gressors (cerebrospinal fluid and white matter). Next, these time series
were entered in a temporal regression into the same dataset. This resulted
in a whole-brain spatial map per network per dataset with regression
coefficients referring to the weight of each voxel being associated with
the characteristic signal change of a specific network. The higher the
value of the coefficient, the stronger the connectivity of this voxel with a
given network. These individual statistical maps were subsequently used
for higher level analysis to examine, for each network separately,
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Fig. 2. Median (red line) and individual (black lines) pharmacokinetic profiles for citalopram (l
young (A) and older (B) subjects. Grey bars illustrate moments of RS-fMRI acquisition post dru
315(within and outside networks) differed between young and older
subjects.
Higher level analysis. To investigate group treatment interaction effects
of citalopram and galantamine we used non-parametric combination
(NPC) as provided by FSL's Permutation Analysis for Linear Models tool
(PALM vs94-alpha) (Pesarin, 1990; Winkler et al., 2014, 2016b). NPC is a
multivariate method that offers the possibility to combine data of sepa-
rate, possibly non-independent tests, such as our multiple time points,
and investigate the presence of joint effects across time points, in a test
that has fewer assumptions and is more powerful than repeated-
measurements analysis of variance (ANOVA) or multivariate analysis of
variance (MANOVA). NPC testing was used in two phases to estimate for
each network whether drug versus placebo effects on connectivity were
significantly different between young and older subjects.
First, tests were performed for each post-dose time point (T¼ 2.5, 3.5,
4.5 and 6 h) separately, using 1000 synchronized permutations, followed
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Fig. 3. Least squares means percent change from baseline profiles of cortisol and prolactin concentrations (with standard errors of the mean as error bars) in young (left) and older
(right) subjects.
B.L. Klaassens et al. NeuroImage 169 (2018) 312–322approximation distribution, thus refining the p-values at the tail further
than otherwise possible with a small number of permutations (Winkler
et al., 2016a). To assess group treatment interaction effects on voxel-
wise functional connectivity with each of the 10 functional networks,
four two-sample t-tests (young adults: drug - placebo versus older adults:
drug - placebo) were performed, one per time point, with average heart
rate (beats/m) per RS-fMRI scan as confound regressor (Khalili-Mahani
et al., 2013). The average of the two baseline RS-fMRI scans was used as
covariate as well, by adding the coefficient spatial map as a
voxel-dependent regressor in the model. This will control for the con-
founding influence of possibly systematic individual differences and
age-related differences at baseline level as recently analyzed and
described in Klaassens et al. (2017b). The same method was applied for
additional investigation of treatment effects (drug versus placebo) within
the group of older adults as was previously done for the group of young
adults (Klaassens et al., 2017a). To that end, four one-sample t-tests (drug
versus placebo) were performed for all post-dose time points (T¼ 2.5,
3.5, 4.5 and 6 h), with average heart rate (beats/m) per RS-fMRI scan and
the average of the two baseline RS-fMRI scans as covariates.
Second, to analyze effects across time, the tests for the four time
points were combined non-parametrically via NPC using Fisher's
combining function (Fisher, 1932) and the same set of synchronized
permutations as mentioned above. A liberal mask was used to investigate
voxels within the MNI template, excluding voxels belonging to cerebro-
spinal fluid. Threshold-free cluster enhancement was applied to the tests
at each time point and after the combination, and the resulting voxelwise
statistical maps were corrected for the familywise error rate using the
distribution of the maximum statistic (Smith and Nichols, 2009; Winkler
et al., 2014). Voxels were considered significant at p-values < 0.05,
corrected.316Results
Pharmacokinetics
Table 1 provides an overview of the PK parameters in young and older
subjects, and the statistical outcomes of group analyses. In comparison to
the young subjects, the Tmax of galantamine occurred significantly later in
the older adults (p< .001). There were no further pharmacokinetic dif-
ferences between young and older subjects. Fig. 2 shows individual and
median PK time profiles.Cortisol and prolactin
There was a significant group treatment interaction effect of cit-
alopram and galantamine on cortisol (p< .05). In comparison to the
young subjects, the increase in cortisol was significantly larger in the
older adults after citalopram and galantamine, relative to placebo.
There was no significant group treatment interaction effect on
prolactin. In both groups, there was an increase in prolactin after cit-
alopram versus placebo (p< .005). Galantamine did not affect the level
of prolactin. See Fig. 3 for cortisol and prolactin levels in young and older
subjects.NeuroCart® test battery
Supplementary Table S-1 provides an overview of all NeuroCart®
results. There were no convincing significant group treatment inter-
action effects after galantamine or citalopram versus placebo on any
NeuroCart® measure.
Fig. 4. Decreased connectivity in young (A) and older subjects (B) after citalopram versus placebo was observed between the sensorimotor network (shown in green) and regions as shown
in blue. Plots visualize the corresponding average time profiles of changes in functional connectivity for citalopram (dotted line) and placebo (continuous line) conditions (z-values with
standard errors of the mean as error bars). Coronal and axial slices are displayed in radiological convention (left¼ right).
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Serotonergic effects
There was no group treatment interaction effect of citalopram on
functional network connectivity. We did find main treatment effects of
citalopram on connectivity with the sensorimotor network in both
groups. Within the young subjects, citalopram decreased connectivity
between the sensorimotor network and supplementary motor area, pre-
and postcentral gyrus, anterior and posterior cingulate cortex (ACC and
PCC), precuneus, medial and orbital frontal cortex, and cerebellum.
Within the older adults, citalopram decreased connectivity between the
sensorimotor network and supplementary motor area, pre- and post-
central gyrus, ACC, PCC, cingulate gyrus, precuneus, superior frontal
gyrus and frontal orbital cortex (Fig. 4). Specifications and extent of
significant citalopram effects are summarized in Table 2.
Cholinergic effects
An interaction effect of galantamine was found for one visual network
(occipital pole). An increase in connectivity after galantamine versusTable 2
Overview of significant citalopram effects on functional connectivity as estimated with thresho






ACC, PCC, precuneus, SMA, post- and precentral g
cerebellum
L Inferior temporal gyrus, inferior and temperooccip







SMA, superior and middle frontal gyrus, ACC, PCC
L/R/
M
Precuneus, postcentral gyrus, posterior cingulate g
L Temporal pole, frontal orbital cortex
R Pre- en postcentral gyrus
R Occipital fusiform gyrus
R Precentral gyrus
R Occipital fusiform gyrus
R Middle frontal gyrus, frontal pole
R Occipital fusiform gyrus
R Precentral gyrus
Abbreviations: L ¼ left, R ¼ right, M ¼ midline, ACC ¼ anterior cingulate cortex, PCC ¼ posterio
2 mm (voxel volume 0.008 mL). * ¼ standardized z-value of the uncorrected peak Fisher-statist
317placebo was significantly larger in the young compared to the older
adults between the occipital visual network and the precuneus, PCC,
postcentral-, angular- and supramarginal gyrus (Fig. 5). Galantamine led
to increased connectivity between the occipital visual network and the
left and right hippocampus, precuneus, thalamus, fusiform gyrus, pre-
central and superior frontal gyrus, PCC and cerebellum in the young
subjects, whereas no significant treatment effect of galantamine on this
network was detected in the group of older adults. Specifications and
extent of significant galantamine effects are summarized in Table 3.
Discussion
To study the influence of older age on neurotransmitter pathways, we
investigated differences in functional network responsiveness to single-
dose serotonergic and cholinergic stimulation between young and older
adults, independent of between-group variation in brain connectivity at
baseline (Klaassens et al., 2017b). We found a significantly weaker
pharmacological effect of galantamine on functional integrity of the oc-
cipital visual network in the older compared to the young subjects. Sinceld-free cluster enhancement (p< .05, corrected).
z* x y z #
voxels
yrus, medial and orbital frontal cortex, 5.23 22 50 16 36214
ital part 3.65 50 46 12 153
3.58 40 74 18 94
4.03 28 42 32 52
, paracingulate gyrus 4.27 36 26 40 4076
yrus, superior parietal lobule 3.52 0 48 64 467
4.54 46 14 18 368
3.34 34 10 30 258
4.29 30 64 16 204
2.76 32 12 68 41
3.65 24 78 18 32
3.43 28 36 34 30
3.43 16 82 26 18
3.33 20 36 42 15
r cingulate cortex, SMA ¼ supplementary motor area. Voxel dimension ¼ 2 mm  2 mm x
ic (NPC) within regions (with # voxels> 10).
Fig. 5. A larger effect on connectivity in young compared to older adults after galant-
amine versus placebo between the occipital visual network (shown in green) and regions
shown in red (top). The plot visualizes the corresponding average time profiles of changes
in functional connectivity per group for galantamine - placebo conditions (delta z-values
with standard errors of the mean as error bars). The 3D images (bottom) show main
galantamine effects per group. Coronal and axial slices are displayed in radiological
convention (left¼ right).
B.L. Klaassens et al. NeuroImage 169 (2018) 312–322the effects of AChEIs depend on intact cholinergic synapses, this finding
might represent the general tendency towards diminished cholinergic
function in the elderly (Decker, 1987; Dumas and Newhouse, 2011). In
contrast, older age had no impact on the response to the SSRI citalopram,
which induced a strong decrease in connectivity with the sensorimotor
network within both groups.
Citalopram
Reduced connections between multiple regions after citalopram
administration is consistent with previous SSRI research in healthy young
individuals (Klaassens et al., 2015; Schaefer et al., 2014). Although these
effects seemed less pronounced in the older adults compared to young
subjects, there was no significant difference in effect between the two
groups on all networks. As an altered serotonergic system in the elderly
has most often been associated with a higher incidence of depression and
sleep disorders (Gareri et al., 2002; Meltzer et al., 1998), one explanation
for this lack of differences is that there was no evidence for any abnor-
mality of mood, anxiety or sleep in both groups as assessed during
screening. The most prominent finding in both samples was a decrease in
connectivity between the sensorimotor network and sensorimotor318regions, precuneus, ACC and PCC (Fig. 4). Similar findings have been
detected in healthy young subjects with the SSRI sertraline, in which,
amongst other networks, sensorimotor network connectivity with the
ACC, PCC, precuneus, central gyri and supplementary motor cortex was
decreased after single-dose administration (Klaassens et al., 2015). Aging
has been shown to alter motor network connectivity, possibly repre-
senting deteriorated motor ability in the elderly (Wu et al., 2007a,
2007b) and leading to the somewhat smaller response in older compared
to young subjects. However, in favor of a rather unaffected serotonergic
system in our healthy group of elderly, we did not find significantly
different changes in sensorimotor connectivity in the much younger
subjects. This relative sparing of serotonergic network responsiveness in
elderly subjects suggests that the reduced effects of galantamine are
indicative of a selective age-related cholinergic decline. Citalopram
caused a decrease in connectivity of cortical midline structures as the
precuneus, ACC, PCC and prefrontal areas, related to self-referential
mechanisms and emotion regulation, which is in line with opposite ob-
servations in (non-elderly) depressed patients (Sundermann et al., 2014)
and indicates that SSRIs might reverse abnormalities in functional con-
nectivity as seen in depression. The effects on sensorimotor connectivity
also denote the well-known involvement of 5-HT pathways in motor
behavior (Sachenko and Khorevin, 2001). For example, an (uncommon)
side effect of SSRIs is the observance of movement disorders (e.g. muscle
twitches), possibly due to direct adverse effects on motor neurons or
enhancement of serotonergic input on dopaminergic pathways (Ander-
son et al., 2009; Hindmarch, 1995; Leo, 1996). In the young subjects,
citalopram also reduced connectivity between the midbrain and left
frontoparietal network (Klaassens et al., 2017a). This effect was
restricted to a discrete region, and a comparable response could not be
detected in the older adults, despite the lack of significant differences
between groups on this network.
Additional measures of cognitive functioning and neuroendocrine
responses were investigated to confirm the presence of neuropharma-
cological effects and improve the understanding of underlying changes in
brain connectivity. There was no difference between young and older
adults in effect of citalopram on performance on the NeuroCart® test
battery. Single dose SSRI administration does not seem to alter behav-
ioral states in young and older subjects differently (Dumont et al., 2005;
Vanlaar et al., 1995). Acute SSRI effects in healthy subjects of all ages are
limited and variable and our protocol did not include more sensitive
measures of SSRI modulation as EEG recordings, REM-sleep and flicker
discrimination tests (Dumont et al., 2005). Since SSRIs are mainly used as
a treatment for depression and anxiety disorders (Carr and Lucki, 2011;
Jacobs and Azmitia, 1992), the most likely change in our study would
have taken place on mood, alertness or calmness as measured with the
VAS. However, such improvements are usually only noticeable after a
mood-specific behavioral challenge (Browning et al., 2007; Capitao et al.,
2015; Harmer et al., 2003) or after a few weeks (Frazer and Benmansour,
2002; Harmer et al., 2009), and accordingly we did not find these effects.
The fact that citalopram had pharmacological effects in both age groups
is demonstrated by increasing levels of cortisol and prolactin. Neuroen-
docrine fluctuations can be regarded as indirect measures of the 5-HT
system state (Seifritz et al., 1996) and a larger increase in cortisol level in
the older compared to young adults might be indicative of some sero-
tonergic disturbances that accompany the process of normal aging.
However, this interpretation is complicated by the fact that elevated
cortisol has been shown to reduce amygdala-medial prefrontal cortex
connectivity (Veer et al., 2012; Wu et al., 2015), which in turn seems to
be related to baseline cortisol levels. As cortisol was slightly but not
significantly lower at baseline in the elderly, this might lead to a stronger
drug effect on cortisol and network connectivity in older compared to
young adults. There are multiple factors that can cause a decrease in
clearance of antidepressants in the elderly (Boyce et al., 2012; Lotrich
and Pollock, 2005). But most of these affect the terminal part of the
concentration-time curve and exposure during multiple dosing. The
duration of our study was limited, and our elderly subjects were
Table 3
Overview of significant galantamine effects on functional connectivity as estimated with threshold-free cluster enhancement (p< .05, corrected).








Precuneus, PCC, pre- and postcentral gyrus, posterior cingulate gyrus, posterior supramarginal gyrus,
superior parietal lobule
4.15 10 36 44 1218
R Lateral occipital cortex, superior division 3.83 28 62 26 224
R Frontal pole 5.13 38 50 28 94
R Cerebellum 4.05 20 68 32 79
R Middle and superior frontal gyrus 4.25 34 0 56 57
M Cerebellum 3.78 4 68 24 55
R Cerebellum 3.80 20 54 34 52








Hippocampus, thalamus, amygdala, precuneus, PCC, lateral occipital cortex, brain stem, fusiform gyrus,
superior and middle frontal gyrus, superior temporal gyrus, pre- and postcentral gyrus and cerebellum
4.86 2 62 26 15341
L Precuneus, posterior cingulate gyrus 3.15 16 52 20 75
L Temporal pole 3.41 58 10 10 18
R Inferior frontal gyrus 3.81 48 14 14 17
L Lateral occipital cortex, superior division 3.98 46 70 26 12
L Central opercular cortex, insular cortex 3.11 46 4 4 12
Abbreviations: L ¼ left, R ¼ right, M ¼ midline, PCC ¼ posterior cingulate cortex. Voxel dimension ¼ 2 mm  2 mm x 2 mm (voxel volume 0.008 mL). * ¼ standardized z-value of the
uncorrected peak Fisher-statistic (NPC) within regions (with # voxels> 10).
B.L. Klaassens et al. NeuroImage 169 (2018) 312–322relatively healthy. Consequently, no differences in pharmacokinetic
profiles were observed between groups, ensuring comparable exposure in
both age groups over the observation period, with similar and limited
variability. Because elderly are known to have an increased expectancy
for SSRI related side effects (Lotrich and Pollock, 2005), we wanted to
provide them with the opportunity to take a lower dose of 20 instead of
30mg of citalopram, by skipping the second 10mg if necessary. How-
ever, all young and older subjects were administered the total dose of
30mg without vomiting or experiencing nausea as measured with the
VAS. This might also be due to the 2mg of granisetron, given 30min
prior to drug administration on all three study days. Granisetron was
added to suppress nausea and vomiting, which could otherwise adversely
affect study procedures or alter network effects. Yet, it cannot be
excluded that the selective 5-HT3 receptor agonist granisetron might
have also altered specific functional responses (Jacobs and Azmitia,
1992).
Galantamine
Whereas galantamine increased brain connectivity in the young
subjects with one visual network (Fig. 5), we could not detect any effects
of galantamine on resting state connectivity in older adults. The cholin-
ergic system is chiefly associated with an age- and dementia-related
decline in memory, learning and attention with evidence pointing to
cholinergic dysfunction in the hippocampus, cortex, the entorhinal area,
the ventral striatum and the basal forebrain (Kasa et al., 1997; Schliebs
and Arendt, 2011). In our young subjects, galantamine altered connec-
tivity with the hippocampus, thalamus and the fusiform gyrus, areas that
are involved in learning and memory (Garoff et al., 2005; Van der Werf
et al., 2000; Wixted and Squire, 2011). ACh release in the primary visual
cortex seems to be relevant for visual processing and learning (Dotigny
et al., 2008; Kang et al., 2014). The findings in the young group are
therefore consistent with studies that show an essential role for cholin-
ergic enhancement in visual attention (Bentley et al., 2003, 2004), visual
episodic memory and recall (Goekoop et al., 2004, 2006; Gron et al.,
2005), processing of novel faces (Kircher et al., 2005; Rombouts et al.,
2002), perceptual processing during working memory (Furey et al.,
2000) and visual orientation (Murphy and Sillito, 1991). The absence of
effect in the elderly might point to attenuated activity of the cholinergic
system, which accompanies the process of normal aging (Muir, 1997).
The sensitivity of the cholinergic system to aging is emphasized by the
detection of clear and very similar serotonergic effects on connectivity in
both young and older adults. An age appropriate decline in cognitive
function was also observed in our older group compared to the young319subjects by investigating the difference in NeuroCart® performance at
baseline level (before pharmacological stimulation), as presented in
Klaassens et al. (2017b). The elderly performed worse on several tests (%
correct on the Adaptive Tracking task, reaction time on the Symbol Digit
Substitution Test, 0-back, 1-back and 2-back task, and number of correct
responses on the 2-back task), relating to decreased attentional, memory
and processing speed capacities. Our observations of reduced connec-
tivity alterations after galantamine in the older adults seem to confirm
the cholinergic hypothesis of cognitive decline during aging (Dumas and
Newhouse, 2011).
Galantamine's mean Tmax in the elderly (mean Tmax: 4.52 1.08)
occurred significantly later than the mean Tmax in the young subjects
(mean Tmax: 2.67 1.11). This delay in pharmacokinetics might have
caused small shifts in the time course of effects, although it is unlikely
that this affected the overall response over the duration of the experi-
ment, which was the basis for all principal analyses and comparisons.
Since the Tmax of galantamine was within the time frame of measure-
ments for both groups, analyzing a combination of data points would be
minimally influenced by different PK timing profiles. As the level and
variability of plasma concentrations, as determined by Cmax and AUC0-
last, in the elderly was generally similar to those in the younger group, it is
implausible that galantamine effects were obscured by pharmacokinetic
dispersion. Moreover, the rise in plasma cortisol after galantamine was
larger in elderly than in young subjects, which was particularly notice-
able at T¼ 2 and T¼ 2.5. Because galantamine has been shown to in-
crease cortisol (Cozanitis et al., 1980), this indicates that galantamine
was absorbed well enough in the older adults to induce pharmacody-
namic effects. Nevertheless, as described earlier this finding may partly
influence the observed network effects (Veer et al., 2012; Wu et al.,
2015). In addition, despite the administration of granisetron, an increase
in nausea, a typical side effect of AChEIs (Dunbar et al., 2006), after
galantamine in both groups provides further support for sufficient drug
concentrations in the older adults. AChEIs are commonly used to treat
cognitive symptoms of Alzheimer's disease (Tan et al., 2014) and in
healthy subjects there is little evidence for neuroenhancement with this
drug (Lanni et al., 2008). A few studies have been performed on AChEI
efficacy in subjects without cognitive disturbances, with inconclusive
and contradicting results in both young and elderly subjects (Beglinger
et al., 2004, 2005; Gron et al., 2005; Lanni et al., 2008; Repantis et al.,
2010). Two measures of the delayed recognition subtest of the Visual
Verbal Learning Test, the number of correct responses and reaction time,
showed a difference between young and older subjects with p< .05.
However, the number of included NeuroCart® tests was large and the
effects were not clearly related to drug levels. Therefore, this marginal
B.L. Klaassens et al. NeuroImage 169 (2018) 312–322result might likely be due to chance, suggesting that AChEI challenges do
not affect cognitive performance differently between young and older
subjects.
Conclusions
The outcomes of this study illustrate the use of resting state connec-
tivity to investigate different neurotransmitter systems, and how these
selectively change with age. The SSRI citalopram affected sensorimotor
network connectivity in both young and older adults, demonstrating that
SSRIs consistently reduce the functional integrity of regions that are
related to motor function and self-reference, regardless of age. The effect
of the AChEI galantamine was restricted to the young subjects, who
showed a response that indicates the contribution of acetylcholine to
perceptual processing and learning mechanisms. We did not observe any
network effects in the elderly, possibly reflecting a diminished cholin-
ergic system that is associated with an age-appropriate decline in mem-
ory and attention. Combining RS-fMRI with pharmacological challenges
and additional outcome measures offers a useful way to investigate age-
related functional processes, which is in line with Geerligs and Tsvetanov
(2017), who recommend to implement an integrative approach in
studying neurocognitive aging instead of merely using fMRI data.
Compared to cognitive performance, RS-fMRI seems to serve as a rela-
tively sensitive measure of drug-induced functional change. Our findings
support the confidence in RS-fMRI as an important tool in psychopha-
rmacological research, and its potential to measure disease specific al-
terations in neurotransmission.
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